Reducing the risk of COVID-19 spread in hospitals, by stopping droplets from spreading

Oral fluorescein as a biomarker for droplet and aerosol spread of COVID-19 within a clinical environment

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10378358

Enrollment

400

Registered

2020-07-08

Start date

2020-11-01

Completion date

Unknown

Last updated

2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing AGP Infections and Infestations

Interventions

The researchers will stain the saliva and nasal secretions with Fluorescein 2%, one drop in the mouth and one in each nostril. The AGP will be performed and the spread of the droplets will be gathered

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients undergoing AGP at Queen Alexandra Hospital 2. Patients in dental faculty University of Portsmouth 3. Aged 18 years or above

Exclusion criteria

Exclusion criteria: 1. Not able to consent to the investigation 2. COVID-19 infection, or symptoms 3. Allergy to fluorescein, or multiple allergies

Design outcomes

Primary

Measure	Time frame
The proportion of patients where the spread of airborne droplets during AGP is > 50 drops on a detection pad at 1 m	—

Countries

England, United Kingdom

Contacts

Public ContactRichard Newsom

richard.newsom@port.ac.uk+44 (0)23 9284 2994

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026